Key Drivers
- Strong Cash Flow
- High Leverage
- Thin Cushion
AIAI Summary
OGN should now be viewed primarily as a merger-arbitrage trade around Sun Pharma's $14.00 cash offer, meaning upside is mostly capped by the tight spread and the real risk is deal delay or failure given the company's weak standalone growth and heavy leverage.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •High Leverage
- •Thin Cushion
OGN generates solid profits and cash flow at reasonable multiples, but high leverage, thin interest coverage, and a large intangible-heavy balance sheet make the equity story risky despite improving operating efficiency.
Price Behavior
Key Price Behavior Insights:
- •Tight Range
- •Firm Support
- •Capped Upside
OGN has drifted modestly higher over the last month, with repeated buying near $13.36-$13.40 and resistance holding near $13.55, so the setup is constructive but still range-bound until it breaks above that level.
Slow, narrow climb from $13.40 to $13.55 suggests consolidation rather than a breakout
Sentiment & News
Key News Insights:
- •Deal scrutiny
- •Biosimilar expansion
- •FDA approvals
Organon drew heavy investor attention as takeover scrutiny intensified, even as it advanced biosimilar approvals and launches and expanded its women's health portfolio.
This mix of M&A uncertainty and steady product execution is likely to keep OGN volatile while supporting the long-term operating story
Similar Companies in Healthcare
Other companies in the same sector with AI ratings